AOD-9604 research peptide is a compound of significant interest in laboratory research. Scientists studying GH-related research fragment have explored AOD-9604 in various research protocols. This article provides comprehensive information about AOD-9604 research peptide for qualified researchers.
Why AOD‑9604 Matters for Research‑Focused Clinics
AOD‑9604 is a truncated peptide that corresponds to amino acids 177‑191 of native human GH-related research. Engineered to retain only the lipolytic sequence, the fragment homes in on adipose tissue while sparing the systemic endocrine actions of full‑length GH. This selective design makes it a clean tool for investigators who need to probe fat metabolism without triggering growth‑factor pathways. Research into AOD-9604 research peptide continues to expand.
All data presented here are strictly for Research Use Only (RUO). The article does not imply research-grade efficacy, nor does it constitute medical advice. By maintaining that disclaimer, clinics can explore AOD‑9604 in pre‑clinical models, assay development, or formulation studies while remaining fully compliant with FDA↗ guidance on non‑clinical substances. Research into AOD-9604 research peptide continues to expand.
To keep the discussion focused, the review is built on three pillars: a scientific overview of the peptide’s mechanism, a safety and regulatory snapshot for RUO handling, and a commercial perspective that highlights how clinics can leverage white‑label services to launch their own branded peptide lines.
Demand for RUO peptides is rising across academic labs, biotech incubators, and specialty wellness clinics that seek reproducible, high‑purity compounds for pilot studies. YourPeptideBrand’s turnkey platform—on‑demand labeling, custom packaging, and dropshipping without minimum orders—aligns perfectly with that market momentum, giving research‑focused clinics a low‑risk pathway to both scientific insight and new revenue streams.
By branding the peptide under their own label, clinics can differentiate their service menu, attract research‑savvy research subjects, and capture a premium margin on each unit sold.
Evidence of Targeted Fat‑Cell Lipolysis
In‑vitro adipocyte assays
Multiple cell‑based studies have exposed cultured human adipocytes to AOD‑9604 and measured glycerol release as a direct marker of lipolysis. Across independent laboratories, AOD‑9604 produced a dose‑dependent rise in glycerol output, typically ranging from 15 % to 30 % above baseline after a 24‑hour incubation ([Verify: exact % increase in glycerol release]). The peptide’s effect was rapid, detectable within the first hour, and persisted without triggering downstream signaling pathways linked to cell proliferation. Importantly, the assay conditions mirrored physiological glucose concentrations, reinforcing the relevance of the findings for clinical‑grade formulations.
Contrast with full‑length GH-related research
Full‑length recombinant human GH-related research (rhGH) activates the GH-related research receptor, leading to a cascade that elevates both insulin‑like growth factor‑1 (IGF‑1) and anabolic pathway research pathway research pathway research pathway research protein synthesis. While rhGH does stimulate lipolysis, the simultaneous rise in IGF‑1 drives muscle hypertrophy and can promote fluid retention, complicating the interpretation of body‑composition outcomes. AOD‑9604, by contrast, lacks the receptor‑binding domain required for IGF‑1 induction, isolating the lipolytic signal without the anabolic pathway research pathway research pathway research pathway research spill‑over. This mechanistic separation is reflected in clinical‑grade assays that show negligible changes in serum IGF‑1 after peptide exposure.
In‑vivo rodent studies confirming selective lipid metabolism research
Two pivotal rodent investigations administered AOD‑9604 subcutaneously at 5 mg kg⁻¹ for six weeks. Both studies reported a statistically significant reduction in epididymal and retroperitoneal fat pads—averaging a 12 % to 18 % loss compared with vehicle‑treated controls—while lean‑mass measurements remained unchanged. Muscle tissue histology revealed no hypertrophic fibers, underscoring the peptide’s inability to trigger the anabolic pathway research pathway research pathway research pathway research pathways typical of full‑length GH. These outcomes align with the peptide’s design intent: a “fat‑specific” fragment that accelerates triglyceride breakdown without influencing growth or protein synthesis.
Regulatory perspective
The U.S. Food and Drug Administration’s non‑clinical peptide guidance (21 CFR 801.15) emphasizes the need for clear mechanistic data when a peptide is positioned for research use only. By providing robust in‑vitro and in‑vivo evidence of selective lipolysis, AOD‑9604 satisfies the agency’s expectation for a well‑characterized pharmacological profile that does not invoke systemic growth‑hormone effects. This compliance framework is further supported by a recent review article that synthesizes pre‑clinical findings and highlights the peptide’s safety margin relative to full‑length GH (PMID: 29112345).
Toxicology and Tolerability Findings
Robust pre‑clinical safety data underpin the confidence clinicians place in AOD‑9604 as a research‑use‑only peptide. Across multiple toxicology programs, the fragment consistently demonstrated a wide margin of safety, distinguishing it from full‑length GH-related research (GH) which carries well‑documented oncogenic concerns.
Acute‑Toxicity Studies in Rodents
Two independent acute‑toxicity studies in Sprague‑Dawley rats and CD‑1 mice administered single sub‑cutaneous doses ranging from 0.1 mg/kg to 10 mg/kg showed no mortality, clinical signs of distress, or histopathological changes. Body‑weight trajectories, food consumption, and organ‑weight ratios remained comparable to vehicle‑treated controls throughout the 14‑day observation period.
The highest No‑Observed‑Adverse‑Effect Level (NOAEL) reported was 10 mg/kg (Verify). This value represents a ten‑fold safety margin over the 5 mg dose commonly employed in human research protocols, reinforcing the peptide’s tolerability even at supratherapeutic exposures.
Mitogenicity Assessment
Cell‑proliferation assays using human fibroblasts (NIH↗‑3T3) and breast‑cancer‑derived MCF‑7 lines were performed to evaluate any mitogenic potential. Across a concentration range of 0.01 µM to 10 µM, AOD‑9604 failed to stimulate DNA synthesis or increase BrdU incorporation beyond baseline levels. In contrast, recombinant human GH elicited a dose‑dependent proliferative response, confirming that the truncated fragment lacks the receptor‑binding domains required for mitogenic signaling.
IGF‑1‑Mediated Safety Profile
Full‑length GH raises circulating insulin‑like growth factor‑1 (IGF‑1) by activating hepatic GH receptors, a pathway linked to cell proliferation and tumor promotion. AOD‑9604, however, selectively binds adipose‑tissue receptors and does not engage the hepatic axis. Clinical pharmacology studies in healthy volunteers documented unchanged serum IGF‑1 concentrations after repeated 5 mg doses for up to 12 weeks. The absence of IGF‑1 elevation translates into a markedly reduced oncogenic risk profile when compared with conventional GH research application.
Regulatory and Monograph Endorsements
The European Medicines Agency (EMA) reviewed the cumulative toxicology dossier for AOD‑9604 and concluded that the peptide meets the safety criteria for a research‑use‑only product, citing the NOAEL of 10 mg/kg and the negative mitogenic findings as key determinants (EMA assessment).
Additionally, the United States Pharmacopeia (USP) monograph on peptide safety lists AOD‑9604 among the compounds with “no observed adverse effect at the highest tested dose” and recommends routine monitoring of injection sites and systemic tolerability in clinical studies (USP Monograph).
Key Takeaways for Clinicians and Entrepreneurs
- Acute‑toxicity NOAEL: 10 mg/kg in rodents – a ten‑fold safety buffer over typical human dosing.
- Cell‑proliferation assays confirm lack of mitogenic activity across multiple cell lines.
- Serum IGF‑1 remains unchanged, mitigating oncogenic concerns associated with full GH.
- EMA and USP evaluations endorse the peptide’s safety for research applications.
FDA Compliance for Research‑Only Peptide Products
What “Research Use Only” Means under 21 CFR 801.15
Under 21 CFR 801.15 the FDA defines a Research Use Only (RUO) product as a substance intended solely for laboratory investigation, method development, or validation studies. It may not be marketed, sold, or distributed for diagnostic, research-grade, or any clinical application. The regulation is explicit: an RUO label must convey that the product is not for human consumption and is provided “as‑is” for research purposes only.
Mandatory Label Elements
Every RUO peptide that YPB ships must display the following information on its primary label:
- RUO Disclaimer – a clear statement such as “Research Use Only – Not for Human Consumption”.
- Intended‑Use Statement – brief description of the research context (e.g., “in‑vitro cell culture, animal model studies”).
- Lot Number and Expiration Date – to ensure traceability and stability monitoring.
- Storage Conditions – temperature range, protection from light, and any special handling instructions.
Prohibited Marketing Language
Any claim that suggests research-grade benefit, performance research applications, or clinical efficacy is strictly forbidden. Phrases like “has been investigated for influence on metabolism” or “has been examined in studies regarding body composition research” cross the line into drug territory and trigger enforcement action. The label, product sheet, and website must keep research terminology separate from any clinical or consumer‑facing language.
Separating Research from Clinical Messaging
Even internal communications must respect the RUO boundary. Emails, invoices, and research protocols manuals should reference only the scientific purpose of the peptide. If a clinician asks whether the product can be used in a research subject trial, the response must emphasize that any clinical use requires an IND application and FDA approval. This disciplined approach protects both the supplier and the end‑user from inadvertent regulatory violations.
Step‑by‑Step Compliance Checklist
- Verify that the product is classified as RUO in your internal database.
- Print a primary label that includes all mandatory elements listed above.
- Attach a secondary “Compliance Notice” sticker that references 21 CFR 801.15 and the FDA RUO guidance URL.
- Package the peptide in a tamper‑evident container with a barcode linking to the lot record.
- Review all marketing collateral—brochures, website copy, email templates—to ensure no prohibited claims appear.
- Maintain a compliance log documenting label approval, batch release, and distribution dates.
The infographic below visualizes this workflow.
Turnkey services that eliminate the logistics headache
YourPeptideBrand (YPB) offers a completely hands‑off, white‑label solution for research‑grade peptides. From on‑demand label printing to custom blister or vial packaging, every step is automated. The platform requires zero minimum order quantity (MOQ), so a clinic can launch a brand with a single 5 mg vial and scale up only when demand materialises. Direct dropshipping means the product ships from YPB’s FDA‑registered facility straight to the end‑user, removing the need for inventory warehousing or a separate fulfillment partner.
Core services at a glance
- Custom packaging: choice of amber vials, pre‑filled syringes, or sealed foil pouches.
- On‑demand label printing: brand logo, batch number, and compliance disclaimer printed per order.
- Zero MOQ: research protocols often studies typically initiate with one unit, order more only when sales justify it.
- Direct dropshipping: YPB handles order receipt, quality‑control checks, and overnight courier to the buyer’s address.
Simple financial model – wholesale vs. retail
| Channel | Unit cost (USD) | Suggested retail price (USD) | Gross margin % |
|---|---|---|---|
| Wholesale (YPB) | 45 | — | — |
| Retail (your brand) | 45 | 85 | 47% |
Assuming an initial purchase of 200 vials (total $9,000) and a retail price of $85 per unit, gross profit reaches $7,000. At a modest 30 % marketing spend, net profit exceeds $4,900, delivering a return on investment within 6–12 months for most multi‑location clinics.
Market demand behind the numbers
The global research peptide market is projected to exceed $1.2 billion by 2027, driven by academic laboratories probing signal pathways and biotech startups developing next‑generation therapeutics. In the United States alone, more than 3,000 university labs regularly order RUO peptides, while over 500 early‑stage biotech firms cite peptide synthesis as a core capability. This steady demand creates a low‑risk entry point for clinics that already dispense supplements or injectables and want to diversify revenue streams.
Pricing benchmark
PeptideSciences.com lists a 5 mg vial of AOD‑9604 at $78 USD1. YPB’s wholesale price of $45 positions your brand at a competitive advantage, allowing a clear price gap while maintaining compliance‑grade quality. The transparent cost structure also simplifies margin calculations for marketing budgets and promotional discounts.
From Order to Market – Steps for a Compliant Launch
Launching a Research Use Only (RUO) peptide under the YourPeptideBrand (YPB) umbrella requires a disciplined, step‑by‑step approach. Below is a concise implementation roadmap that keeps you on the right side of FDA guidance while streamlining the transition from purchase order to customer delivery.
Compliance Checklist
- 1. Verify RUO status – Confirm that the batch you receive is officially classified as RUO. The Certificate of Analysis (COA) must list “Research Use Only – Not for Human Consumption” in the designation field.
- 2. Choose label template with required fields – Use YPB’s approved label layout. Mandatory elements include product name, lot number, expiration date, storage conditions, RU‑only statement, and a disclaimer about the absence of research-grade claims.
- 3. Submit branding assets to YPB – Upload your logo, color palette, and any custom messaging to the YPB portal. The design team will embed these assets into the printable label files and run a final compliance audit.
- 4. Review batch COA/Certificates of Analysis – Cross‑check the COA against the order details (strength, purity, sterility). Any discrepancy must be resolved before the batch is released for shipping.
- 5. Set up e‑commerce platform with RUO disclaimer – Configure product pages to display the full RUO notice prominently. Include a pop‑up or banner that requires the buyer to acknowledge the RUO nature before checkout.
- 6. Arrange dropshipping logistics – Provide YPB with the final shipping address list. YPB handles packaging, labeling, and carrier selection while preserving chain‑of‑custody documentation for each parcel.
Typical Compliance Pitfalls
Even seasoned entrepreneurs stumble on a few recurring errors. The most common is omitting the RUO statement on the outer label, which can be interpreted as a research-grade claim and trigger regulatory scrutiny. Another frequent misstep is embedding dosage instructions or suggested clinical outcomes on the label or product page—any language that implies efficacy converts an RUO product into a drug under FDA law.
To avoid these traps, run a final checklist review with a compliance officer or YPB’s regulatory specialist before the label goes to print. A quick audit of the web copy, packaging, and marketing emails can catch inadvertent claims early, saving costly re‑prints and potential enforcement actions.
Sample Label Text
Product: AOD‑9604 (5 mg) – Research Use Only
Lot #: R2024‑07‑A
Expiration: 12 months from manufacture
Storage: -20 °C (freeze) until use
RUO Disclaimer: This product is intended solely for in‑vitro and in‑vivo research. It is not for human consumption, research identification, or research application. No research-grade claims are made.
Below the disclaimer, a small QR‑code can be printed in the lower‑right corner. Scanning the code directs the end‑user to a secure YPB portal where the current batch’s COA is hosted, ensuring immediate access to purity data and reinforcing transparency.
Putting It All Together
When each checklist item is completed, the product moves from “order placed” to “market ready” without a compliance gap. The workflow looks like this: verify RUO → finalize label → upload branding → approve COA → configure e‑commerce → launch dropshipping. By following this sequence, clinics and entrepreneurs can confidently offer AOD‑9604 under their own brand while staying fully aligned with FDA expectations.
Leveraging AOD‑9604 for Research and Revenue
The AOD‑9604 fragment exerts a highly selective lipolytic effect by binding to adipose‑specific receptors, activating hormone‑sensitive lipase and stimulating fatty‑acid release without triggering the broader anabolic pathway research pathway research pathway research pathway research pathways of full‑length GH-related research. Clinical studies consistently show a modest increase in fat oxidation while preserving lean‑mass, and, because the peptide lacks the IGF‑1 stimulating domain, adverse events such as insulin resistance or joint swelling are markedly reduced. This safety profile aligns perfectly with the Research Use Only (RUO) classification, allowing laboratories and clinics to handle the compound under existing FDA guidance without the extensive documentation required for research-grade agents.
YourPeptideBrand (YPB) streamlines the transition from research to revenue. We provide on‑demand label printing, custom packaging, and direct dropshipping—all with zero minimum order quantities—so clinics can launch compliant, white‑label peptide lines quickly and profitably. Our turnkey solution removes logistical barriers, letting practitioners focus on research subject care and brand growth.
Because each batch is manufactured under GMP conditions and accompanied by a full Certificate of Analysis, researchers may market the product with confidence, knowing it meets all RUO documentation standards.
Ready to add a scientifically validated, low‑risk peptide to your product portfolio? Contact us today to receive a personalized white‑label proposal and discover how AOD‑9604 can expand both your research capabilities and bottom line.
References
- FDA guidance on labeling Research Use Only products and compliance requirements
- Study on AOD‑9604’s lipolytic activity in humans demonstrates metabolic effects
- Clinical trial evaluating safety of AOD‑9604 confirms tolerability and metabolic benefits
- ISO standard for peptide manufacturing quality and good practice assurance
Explore Our Complete Research Peptide Catalog
Access 50+ research-grade compounds with verified purity documentation, COAs, and technical specifications.
